Brooke Bloomfield
Family · Sebewaing, MINPI 1578117594
Payments from drug & device makers
Across 81 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$423
- Otsuka America Pharmaceutical, Inc.$182
- GSK$135
- Lilly USA, LLC$95
- AbbVie$82
- Axsome Therapeutics, Inc.$59
- plus $454 from 16 others
What the payments were for
- Food & beverage$1,430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $423 |
| Otsuka America Pharmaceutical, Inc. | 8 | $182 |
| GSK | 9 | $135 |
| Lilly USA, LLC | 6 | $95 |
| AbbVie | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Pfizer | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $37 |
| Amgen(2 entities) | 2 | $36 |
| Exact Sciences | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Bioventus LLC | 1 | $24 |
| Insulet Corporation | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Alkermes, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
How this compares
$1,430 in reported general payments places this provider in the 75th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $58,921 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $24,009 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $23,101 |
| TrulicityDulaglutide | 11 | $16,032 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $12,353 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,061 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $1,143 |
| Potassium Chloride | 40 | $1,132 |
| Levothyroxine Sodium | 97 | $987 |
| Atorvastatin Calcium | 90 | $966 |
| Metoprolol Succinate | 55 | $914 |
| Losartan Potassium | 81 | $762 |
| Tamsulosin Hcl | 24 | $758 |
| Omeprazole | 79 | $733 |
| Ventolin HfaAlbuterol Sulfate | 13 | $701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $423 | $58,92134 claims |
| GSKTrelegy Ellipta | $135 | $23,10128 claims |
| Lilly USA, LLCTrulicity | $95 | $16,03211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,657 family providers in Michigan.
Other family in Sebewaing
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.